Stimulated by the findings of aberrantly methylated CDH1[19] and SFRPs[16] as well as our own evidence on hypermethylation of DKK2 and DKK3 in primary CLL, we quantitatively characterised the methylation status and the expression of the Wnt/β-catenin pathway inhibitors. This evidence concerns the gene DKK2 and B-cell chronic lymphocytic leukemia.